Deal Snapshot
UCB TO ACQUIRE RA PHARMACEUTICALS
Friday 11 October 2019

Brussels, Belgium-based biopharmaceutical company UCB has agreed to merge with Massachusetts, US-based clinical-stage biopharmaceutical company Ra Pharmaceuticals Inc. (NASDAQ: RARX), the company said.
Under the terms of the agreement, Ra Pharma shareholders will receive USD 48 in cash for each Ra Pharma share at closing or approximately USD 2.5bn, which represents a transaction value of approximately USD 2.1bn, net of Ra Pharma cash.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 11/10/2019
Target: Ra Pharmaceuticals Inc
Country: USA
Deal Size: 2.1bn (USD)
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing: Cash
Status: Agreed
Vendor:
Buyer: UCB
Buyer Advisor: Bank of America Merrill Lynch , Lazard , Covington and Burling
Comment:


Options